History
  • 2004
  • 2006
  • 2007
  • 2012
  • 2017
  • 2019
  • 2023
  • 2024
2004

Rompharm began operations as a pharmaceutical manufacturer with its first GMP-approved facility, consisting of two production lines: one for sterile solutions/suspensions (eye drops) and the other for non-sterile solutions/suspensions (oral drops, nasal drops/spray, topical solution/spray). These two lines have a capacity to release 30 million units per year.

Due to increasing market demands, Rompharm has acquired high-tech equipment, achieving a production capacity of 64 million units yearly.
2006, September
Commissioned its second facility for solid dosage forms, powders, granules, or pellets, conditioned in capsules, sachets, or bottles (dry syrups).
2007, December
Started its third facility for injectable solutions, produced aseptically or with terminal sterilization, with a capacity of 100 million ampoules per year.
2012
A new facility was built to manufacture prefilled syringes and solutions for infusion in glass vials. The prefilled syringes line, with an output of more than 100 million units per year, accommodates a wide range of filling volumes from 0.3ml to 20ml. The line for infusions in glass containers, with an output of more than 20 million units per year, manages volumes ranging from 2ml to 250ml.
2017 - 2018
Rompharm certified two new complete manufacturing lines for sterile solutions aseptically prepared and conditioned in mono-doses with a fill volume between 0.1 and 3ml, as well as a complete manufacturing line for freeze-dried products in glass vials.
2019
A second fully automated lyophilization line was commissioned, significantly expanding its capacity to produce freeze-dried pharmaceutical products.
2023
The capacity of the lyophilization line was doubled by installing a second lyophilizator, reinforcing its commitment to consistent, high-quality pharmaceutical production.
2024

Rompharm completed its new oncology products plant. This state-of-the-art facility is equipped to produce specialized oncology medications, including injectable solutions in vials and freeze-dried products. The plant's capabilities and quality assurance processes are designed to deliver safe and effective treatment to healthcare providers and patients worldwide while safeguarding personnel at the highest level. We have doubled our secondary packaging capacity as well as our ophthalmic capacity to 110 million units per year.

Additionally, the company finalized the construction of its new manufacturing plant in Uzbekistan, which was EU GMP inspected. This plant not only expands Rompharm'smanufacturing capabilities but also enables the company to serve new markets with its range of pharmaceutical products.
Quality system
Rompharm's philosophy is oriented towards product quality and compliance with GMP throughout the entire manufacturing and distribution process, along with adherence to other regulations (such as EC Directive 2003/94/EC). Our success is based on implementing modern technologies and maintaining a comprehensive quality system.
A key component of our quality system is our personnel. Their skills and creative potential are more valuable than our assets and equipment, making each employee an integral part of the quality assurance system.






Global presence
30
partners
60
export countries
 —
24
european
160
products
Rompharm's product range is aligned with the market's actual and potential capacity, as well as the level and prospects of demand, marketing products in 60+ countries. Most of our products are generic medicines.
Our products are competitive compared to available analogs in terms of price and quality.
Rompharm is expanding its product range and aiming to grow its sales in the EU market by collaborating with strategic partners.
Rompharm Company looks optimistically toward establishing commercial relations with distributors of pharmaceutical products and is open to long-lasting mutual collaborations.